287 related articles for article (PubMed ID: 27655686)
1. Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism.
Liu J; Chen G; Pelicano H; Liao J; Huang J; Feng L; Keating MJ; Huang P
Oncotarget; 2016 Nov; 7(44):71378-71389. PubMed ID: 27655686
[TBL] [Abstract][Full Text] [Related]
2. Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms.
Zhang W; Pelicano H; Yin R; Zeng J; Wen T; Ding L; Huang R
Mol Med Rep; 2015 Nov; 12(5):7374-88. PubMed ID: 26458979
[TBL] [Abstract][Full Text] [Related]
3. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.
Trachootham D; Zhang H; Zhang W; Feng L; Du M; Zhou Y; Chen Z; Pelicano H; Plunkett W; Wierda WG; Keating MJ; Huang P
Blood; 2008 Sep; 112(5):1912-22. PubMed ID: 18574029
[TBL] [Abstract][Full Text] [Related]
4. Phenethyl isothiocyanate induces DNA damage-associated G2/M arrest and subsequent apoptosis in oral cancer cells with varying p53 mutations.
Yeh YT; Yeh H; Su SH; Lin JS; Lee KJ; Shyu HW; Chen ZF; Huang SY; Su SJ
Free Radic Biol Med; 2014 Sep; 74():1-13. PubMed ID: 24952138
[TBL] [Abstract][Full Text] [Related]
5. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
6. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.
Knittel G; Rehkämper T; Korovkina D; Liedgens P; Fritz C; Torgovnick A; Al-Baldawi Y; Al-Maarri M; Cun Y; Fedorchenko O; Riabinska A; Beleggia F; Nguyen PH; Wunderlich FT; Ortmann M; Montesinos-Rongen M; Tausch E; Stilgenbauer S; P Frenzel L; Herling M; Herling C; Bahlo J; Hallek M; Peifer M; Buettner R; Persigehl T; Reinhardt HC
Nat Commun; 2017 Jul; 8(1):153. PubMed ID: 28751718
[TBL] [Abstract][Full Text] [Related]
7. Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.
Prinz C; Vasyutina E; Lohmann G; Schrader A; Romanski S; Hirschhäuser C; Mayer P; Frias C; Herling CD; Hallek M; Schmalz HG; Prokop A; Mougiakakos D; Herling M
Mol Cancer; 2015 Jun; 14():114. PubMed ID: 26041471
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
9. Alterations of mitochondrial biogenesis in chronic lymphocytic leukemia cells with loss of p53.
Ogasawara MA; Liu J; Pelicano H; Hammoudi N; Croce CM; Keating MJ; Huang P
Mitochondrion; 2016 Nov; 31():33-39. PubMed ID: 27650502
[TBL] [Abstract][Full Text] [Related]
10. Loss of p53 and altered miR15-a/16-1MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells.
Liu J; Chen G; Feng L; Zhang W; Pelicano H; Wang F; Ogasawara MA; Lu W; Amin HM; Croce CM; Keating MJ; Huang P
Leukemia; 2014 Jan; 28(1):118-28. PubMed ID: 23608884
[TBL] [Abstract][Full Text] [Related]
11. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.
Liu PP; Liu J; Jiang WQ; Carew JS; Ogasawara MA; Pelicano H; Croce CM; Estrov Z; Xu RH; Keating MJ; Huang P
Oncogene; 2016 Oct; 35(43):5663-5673. PubMed ID: 27065330
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
13. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
[TBL] [Abstract][Full Text] [Related]
14. Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia.
Opel D; Schnaiter A; Dodier D; Jovanovic M; Gerhardinger A; Idler I; Mertens D; Bullinger L; Stilgenbauer S; Fulda S
Int J Cancer; 2015 Dec; 137(12):2959-70. PubMed ID: 26096065
[TBL] [Abstract][Full Text] [Related]
15. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
Lee HJ; Gallardo M; Ma H; Zhang X; Larsson CA; Mejia A; Hornbaker MJ; Qi Y; Su X; Pageon LR; Quintas-Cardama A; Post SM
Blood Cancer J; 2016 Jun; 6(6):e434. PubMed ID: 27284738
[TBL] [Abstract][Full Text] [Related]
16. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
Tam CS; Stilgenbauer S
Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
18. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway.
Zenz T; Mohr J; Edelmann J; Sarno A; Hoth P; Heuberger M; Helfrich H; Mertens D; Dohner H; Stilgenbauer S
Leuk Lymphoma; 2009 Mar; 50(3):510-3. PubMed ID: 19347737
[TBL] [Abstract][Full Text] [Related]
19. Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances.
Perez-Chacon G; Martinez-Laperche C; Rebolleda N; Somovilla-Crespo B; Muñoz-Calleja C; Buño I; Zapata JM
Clin Cancer Res; 2016 Jan; 22(1):134-45. PubMed ID: 26324744
[TBL] [Abstract][Full Text] [Related]
20. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.
Balatti V; Rizzotto L; Miller C; Palamarchuk A; Fadda P; Pandolfo R; Rassenti LZ; Hertlein E; Ruppert AS; Lozanski A; Lozanski G; Kipps TJ; Byrd JC; Croce CM; Pekarsky Y
Proc Natl Acad Sci U S A; 2015 Feb; 112(7):2169-74. PubMed ID: 25646413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
